Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

v2.4.0.6
Condensed Consolidated Financial Statement Detail (Tables)
 3 Months Ended
Mar. 31, 2013
Condensed Consolidated Financial Statement Detail [Abstract]  
Outstanding securities considered anti-dilutive

Potentially dilutive securities are excluded from the calculation of loss per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

 
 
Three Months Ended March 31,
 
 
 
2013
 
 
2012
 
Common stock options and restricted stock units
 
 
6,459
 
 
 
5,722
 
Warrants for common stock
 
 
16,176
 
 
 
5,457
 
Total
 
 
22,635
 
 
 
11,179
 

Accrued liabilities
Accrued liabilities consisted of the following at March 31, 2013 and December 31, 2012 (in thousands):

 
 
March 31,
2013
 
 
December 31,
2012
 
Accrued payroll and other benefits
 
$
2,169
 
 
$
2,461
 
Accrued management incentive compensation
 
 
1,086
 
 
 
3,978
 
Accrued clinical trial costs
 
 
746
 
 
 
4,702
 
Other
 
 
1,409
 
 
 
1,904
 
Total
 
$
5,410
 
 
$
13,045